Axel Finckh - AILBRY - Article Search

Results for 'Axel Finckh' :

Cost-Effectiveness of Biologics as First-Line Treatment of Rheumatoid Arthritis: Case Closed?

Publication Year: 2009

DOI: https://doi.org/10.7326/0003-4819-151-9-200911030-00013

Abstract:

Authors:
- Maarten Boers
Anti–Cyclic Citrullinated Peptide Antibodies in the Diagnosis of Rheumatoid Arthritis: Bayes Clears the Haze

Publication Year: 2007

DOI: https://doi.org/10.7326/0003-4819-146-11-200706050-00011

Abstract:

Authors:
- Axel Finckh
- Matthew H. Liang
Cost-Effectiveness of Biologics in Early Rheumatoid Arthritis

Publication Year: 2010

DOI: https://doi.org/10.7326/0003-4819-152-5-201003020-00018

Abstract:

Authors:
- Axel Finckh
The American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials

Publication Year: 2006

DOI: https://doi.org/10.1002/art.21625

Abstract:

Authors:
- Matthew H. Liang
- Peter H. Schur
- Paul R. Fortin
- E. William St. Clair
- James E. Balow
- Karen H. Costenbader
- Leslie J. Crofford
- Paola de Pablo
- Mary Anne Dooley
- Axel Finckh
- Caroline Gordon
- Ingrid E. Lundberg
- A Meyrier
- Ola Nived
- Claudio Ponticelli
- Matthias Schneider
- Ajay Singh
- Daniel J. Wallace
Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now

Publication Year: 2005

DOI: https://doi.org/10.7326/0003-4819-142-3-200502010-00013

Abstract:

Authors:
- Axel Finckh
- Mark D. Aronson
Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women

Publication Year: 2006

DOI: https://doi.org/10.1002/art.22210

Abstract:

Authors:
- Axel Finckh
- Glinda S. Cooper
- Lori B. Chibnik
- Karen H. Costenbader
- Julie Watts
- Helen Pankey
- Patricia A. Fraser
- Elizabeth W. Karlson
POS1069 SYSTEMATIC LITERATURE REVIEW INFORMING THE EULAR POINTS TO CONSIDER TASK FORCE ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

Publication Year: 2023

DOI: https://doi.org/10.1136/annrheumdis-2023-eular.4884

Abstract:

Authors:
- E. Sebbag
- J. Molina Collada
- Kim Lauper
- Daniel Aletaha
- Johan Askling
- Karolina Benesova
- Heidi Bertheussen
- Samuel Bitoun
- E. C. Bolek
- Gerd R Burmester
- Helena Canhão
- Katerina Chatzidionysiou
- Jeffrey R. Curtis
- F.X. Danlos
- V. Guimaraes
- Merete Lund Hetland
- Florenzo Iannone
- Marie Kostine
- Tue Wenzel Kragstrup
- Tore K Kvien
- Anne C. Regierer
- Hendrik Schulze‐Koops
- Lucía Silva-Fernández
- Zoltán Szekanecz
- Maya H Buch
- Axel Finckh
- Jacques‐Eric Gottenberg
AB0206 DESCRIPTION AND FOLLOW-UP OF RHEUMATOID ARTHRITIS PATIENTS WHO STOPPED B/TSDMARD THERAPY, STRATIFIED BY CESSATION REASON

Publication Year: 2021

DOI: https://doi.org/10.1136/annrheumdis-2021-eular.898

Abstract:

Authors:
- Theresa Burkard
- Enriqueta Vallejo-Yagüe
- Thomas Hügle
- Axel Finckh
- Andrea M. Burden
OP0045 EULAR POINTS TO CONSIDER ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

Publication Year: 2023

DOI: https://doi.org/10.1136/annrheumdis-2023-eular.4789

Abstract:

Authors:
- E. Sebbag
- K. Lauper
- J. Molina Collada
- Daniel Aletaha
- Johan Askling
- Karolina Benesova
- Heidi Bertheussen
- Samuel Bitoun
- E. C. Bolek
- Gerd R Burmester
- Helena Canhão
- Katerina Chatzidionysiou
- J. Curtis
- F.X. Danlos
- V. Guimaraes
- Merete Lund Hetland
- Florenzo Iannone
- Marie Kostine
- Tue Wenzel Kragstrup
- Tore K Kvien
- Anne C. Regierer
- Hendrik Schulze‐Koops
- Lucía Silva-Fernández
- Z. Szekanecz
- Maya H Buch
- Axel Finckh
- Jacques-Éric Gottenberg
OP0105 HPR DO MOBILE APPS IMPROVE SHARED DECISION MAKING AND DISEASE MANAGEMENT IN THE RHEUMATIC DISEASES? AN EVALUATION OF APPS IN A SWISS RHEUMATOLOGY REGISTRY

Publication Year: 2019

DOI: https://doi.org/10.1136/annrheumdis-2019-eular.382

Abstract:

Authors:
- Yomei Shaw
- Delphine S. Courvoisier
- Almut Scherer
- Adrian Ciurea
- Thomas Lehmann
- Veronika K. Jaeger
- Ulrich A. Walker
- Axel Finckh
POS0668 REAL WORLD EFFECTIVENESS OF BARICITINIB IN THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)

Publication Year: 2021

DOI: https://doi.org/10.1136/annrheumdis-2021-eular.1781

Abstract:

Authors:
- B. Gilbert
- D. Courvoisier
- D. Mongin
- K. Lauper
- Clémentine Perrier
- Rüdiger Müller
- Axel Finckh
AB0262 SERUM CALPROTECTIN AS A MARKER OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS

Publication Year: 2019

DOI: https://doi.org/10.1136/annrheumdis-2019-eular.1108

Abstract:

Authors:
- Matthias Jarlborg
- Delphine S. Courvoisier
- Céline Lamacchia
- Laura Martínez-Prat
- Chelsea Bentow
- Michael Mähler
- Axel Finckh
- Cem Gabay
- Michael J. Nissen
SAT0588 COMPARATIVE EFFECTIVENESS RESEARCH IN OBSERVATIONAL SETTINGS: EVALUATING TWO NEW METHODS TO ANALYSE RESPONSE RATES

Publication Year: 2019

DOI: https://doi.org/10.1136/annrheumdis-2019-eular.1211

Abstract:

Authors:
- Kim Lauper
- Denis Mongin
- Cem Gabay
- Axel Finckh
- Delphine S. Courvoisier
Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients

Publication Year: 2010

DOI: https://doi.org/10.1016/j.jbspin.2010.02.021

Abstract:

Authors:
- Axel Finckh
- Jean Dudler
- Felix Wermelinger
- Adrian Ciurea
- Diego Kyburz
- Cem Gabay
- Sylvette Bas
OP0231 COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-POT” STUDY)

Publication Year: 2020

DOI: https://doi.org/10.1136/annrheumdis-2020-eular.346

Abstract:

Authors:
- Kim Lauper
- Denis Mongin
- Sytske Anne Bergstra
- D. Choquette
- Cătălin Codreanu
- Diederik De Cock
- Lene Dreyer
- Ori Elkayam
- Kimme L Hyrich
- Florenzo Iannone
- Nevsun İnanç
- EK Kristianslund
- TK Kvien
- B.F. Leeb
- G. Lukina
- Dan Nordström
- Karel Pavelká
- Manuel Pombo‐Suárez
- Žiga Rotar
- María José Santos
- Anja Strangfeld
- D. Courvoisier
- Axel Finckh

Found 95 results in 0.187 seconds

What is Boolean Searches

Including any of the words AND, OR, or NOT in any of your searches will enable boolean search. Those words must be UPPERCASE. You can use this in all searches, including using the search parameter, and using search filters.

This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks. Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and stop-word removal (be sure to use double quotation marks — "). Using parentheses will specify order of operations for the boolean operators. Words that are not separated by one of the boolean operators will be interpreted as AND.

Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard and fuzzy searches using *, ? or ~ are not allowed; these characters will be removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as described above, including stemming and removal of stop words.

Example Search

Search for works that mention "elmo" and "sesame street", but not the words "cookie" or "monster":

AILBRY - Article Search

Results for 'Axel Finckh' :

Cost-Effectiveness of Biologics as First-Line Treatment of Rheumatoid Arthritis: Case Closed?

Anti–Cyclic Citrullinated Peptide Antibodies in the Diagnosis of Rheumatoid Arthritis: Bayes Clears the Haze

Cost-Effectiveness of Biologics in Early Rheumatoid Arthritis

The American college of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials

Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now

Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women

POS1069 SYSTEMATIC LITERATURE REVIEW INFORMING THE EULAR POINTS TO CONSIDER TASK FORCE ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

AB0206 DESCRIPTION AND FOLLOW-UP OF RHEUMATOID ARTHRITIS PATIENTS WHO STOPPED B/TSDMARD THERAPY, STRATIFIED BY CESSATION REASON

OP0045 EULAR POINTS TO CONSIDER ON THE INITIATION OF TARGETED THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES AND A HISTORY OF CANCER

OP0105 HPR DO MOBILE APPS IMPROVE SHARED DECISION MAKING AND DISEASE MANAGEMENT IN THE RHEUMATIC DISEASES? AN EVALUATION OF APPS IN A SWISS RHEUMATOLOGY REGISTRY

POS0668 REAL WORLD EFFECTIVENESS OF BARICITINIB IN THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)

AB0262 SERUM CALPROTECTIN AS A MARKER OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS

SAT0588 COMPARATIVE EFFECTIVENESS RESEARCH IN OBSERVATIONAL SETTINGS: EVALUATING TWO NEW METHODS TO ANALYSE RESPONSE RATES

Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients

OP0231 COMPARATIVE EFFECTIVENESS OF JAK-INHIBITORS, TNF-INHIBITORS, ABATACEPT AND IL-6 INHIBITORS IN AN INTERNATIONAL COLLABORATION OF REGISTERS OF RHEUMATOID ARTHRITIS PATIENTS (THE “JAK-POT” STUDY)

What is Boolean Searches

Example Search